Company intelligence / Profile preview

Menten AI

San Francisco, California, United Statesmenten.ai ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

The company has demonstrated in vitro and in vivo validation of their platform for complex drug targets such as protein-protein interfaces. They have created multiple hit molecules across various drug targets including an anti-viral peptide for COVID-19.

Therapeutic areas: Infectious Diseases
Modalities: Peptide macrocyclesCyclic peptides
Industry: Biotech

Partnerships

Bristol Myers Squibb

Beyond the preview

Go deeper on Menten AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Menten AI.

Explore the full profile